Kroger: Sales Were Cut, but the Profit Engine Didn't Blink

Kroger just did something that sounds like a downgrade but reads like a split decision. On September 11, the grocer trimmed its full-year same-store-sales outlook to growth of just 0.2% to 0.8% — down from the 1.0% to 2.0% it had promisedand the shares slipped on the news, landing near the low end of a 52-week range whose high was $76.58. That is the headline most investors will carry. But look at what did not change: Kroger reaffirmed full-year adjusted earnings of $5.10 to $5.30 a share and free cash flow of $2.7 to $2.9 billion, while it raised its dividend by 11%, and spent $1 billion buying back stock in the quarter.

The two things do not fit together — a flat grocer and a growing profit — until you see the mechanism underneath. Here is what the quarter actually showed.

Identical sales barely moved; earnings kept climbing

Kroger's fiscal second quarter, ended August 15, produced identical sales excluding fuel of just 0.2%, against 3.4% a year earlier. Total sales rose to $34.6 billion from $33.9 billion. On the surface that is a company standing still.

Yet adjusted EPS came in at $1.09, up 5% from $1.04 a year ago and ahead of the roughly $1.05 to $1.06 analysts expected. Operating profit rose to $971 million from $863 million. The gap between a near-flat top line and a growing bottom line is the whole story: Kroger is increasingly converting a stagnant store business into higher profit per share elsewhere, and the quarter gives three concrete places where that happens.

Adjusted eCommerce sales grew 20%, and management says that business is now profitable rather than a margin drag. Kroger Precision Marketing — the media arm that sells ad space on its customer data — grew profit 24%. Pharmacy mix and sourcing helped the margin side, while management pointed to operating leverage in the digital and media businesses. Add the 11% dividend increase and $1 billion of buybacks, and the earnings line is doing the heavy lifting that a 0.2% comp feed can't.

Part of the weak sales number is not retail demand at all. Kroger attributes roughly 138 basis points of the identical-sales shortfall to the Inflation Reduction Act, which reduced out-of-pocket costs for Medicare prescription drugs and thereby cut pharmacy revenue. Strip that regulatory drag, and the underlying store trend is a bit firmer than the headline comp suggests — though still slow. That matters for the bull case, because it says the comp cut is partly an accounting of a pharmacy-pricing law, not necessarily a shopper exodus.

Cheap because it's low-growth, which is the whole question

At about $58, Kroger trades for roughly 11 times the midpoint of its reaffirmed EPS range, with a dividend yield near 2.5% and free cash flow that comfortably covers the payout and the buyback program. The contrast with the growth grocers is stark: Costco trades around 40 times forward earnings, Walmart in the high 20s to low 30s. The market has priced Kroger for a no-growth grocery business.

That is the crux. A low multiple on a mature grocer is not automatically a bargain — it can be the market correctly pricing stagnation. The bear case writes itself: 0.2% identical sales is barely growth at all, margin discipline eventually hits a floor, and even high-quality earnings strung across a flat top line leave a company compounding at grocery-industry rates. If deflation and competition from Walmart, Costco, and Amazon keep squeezing, then ~11 times is roughly fair, not cheap.

The bull case is that the reset has run ahead of the damage. The stock is down about 20% over the past four months and roughly 14% over the past year, while adjusted EPS guidance held, cash flow held, and the company keeps returning capital. The regulatory headwind is a known, disclosed drag rather than a collapse in demand. And the profit engine now has diversifying gears — eCommerce, media, pharmacy mix — that a grocer historically did not have. When the market cuts a sales number and leaves the earnings number intact, the question is whether it overreacted to the metric it can see and underweighted the one that pays the dividend.

What would change the read

The honest position here is that the valuation has absorbed the bad news but the business has not yet proved it deserves a re-rating. The full-year range now depends on "improving sales momentum," as CEO Greg Foran put it, and he conceded there is "more work to do." The next two to four quarters are the proof window: whether identical sales firm past the ~1.4% ex-IRA level, whether the IRA pharmacy drag fades as comparisons ease, and whether the reaffirmed $5.10 to $5.30 holds. The margin improvement is real but finite; a stock this cheap stays cheap only until the comp line inflects.

For an investor deciding whether this is a fallen-stock bargain or a value trap, the line is drawn by the top line, not the income statement. Kroger can keep cutting costs and returning capital for a long time at ~11 times earnings — that is durable support. But a grocer re-rates upward only when shoppers come back. Until the comps turn, cheap is the correct description, and the multiple is doing the work that earnings growth should eventually have to do.